Literature DB >> 27437281

A Case of Erythroderma Secondary to Hypereosinophilia.

Mohammed Shafi Abdulsalam1, Hari Chandana Ghanta2, Prabu Pandurangan3, Maya Menon4, Sheba S K Jacob5.   

Abstract

Hypereosinophilic syndrome (HES) is a myeloproliferative disorder characterised by marked peripheral eosinophilia and end organ damage attributable to eosinophilia without secondary cause. Early recognition and treatment are essential to prevent morbidity and mortality. Cytoreduction with Steroids, Hydroxyurea and Imatinib are the main stay of treatment. Molecular studies like Fip1-like-1 fused with platelet derived growth factor receptor alpha (FIP1L1-PDGFRα) etc., are recommended in view of therapeutic implication. In this paper we report a rare case of HES developing in a lady 6 months after surgical removal of lymphangioma of spleen, which in itself is rare.

Entities:  

Keywords:  Adrenal insufficiency; Cytoreduction; Lymphangioma of spleen; Tissue eosinophilia

Year:  2016        PMID: 27437281      PMCID: PMC4948457          DOI: 10.7860/JCDR/2016/19057.7770

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  10 in total

1.  Response to imatinib mesylate in patients with hypereosinophilic syndrome.

Authors:  Maryam Arefi; Juan L García; M Montserrat Briz; Felipe de Arriba; Juan N Rodríguez; Guillermo Martín-Núñez; Joaquín Martínez; Javier López; Julio G Suárez; M José Moreno; M Angeles Merino; Norma C Gutiérrez; Jesús Marίa Hernández-Rivas
Journal:  Int J Hematol       Date:  2012-07-18       Impact factor: 2.490

Review 2.  The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature.

Authors:  M J Chusid; D C Dale; B C West; S M Wolff
Journal:  Medicine (Baltimore)       Date:  1975-01       Impact factor: 1.889

3.  Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes.

Authors:  Peter Valent; Amy D Klion; Hans-Peter Horny; Florence Roufosse; Jason Gotlib; Peter F Weller; Andrzej Hellmann; Georgia Metzgeroth; Kristin M Leiferman; Michel Arock; Joseph H Butterfield; Wolfgang R Sperr; Karl Sotlar; Peter Vandenberghe; Torsten Haferlach; Hans-Uwe Simon; Andreas Reiter; Gerald J Gleich
Journal:  J Allergy Clin Immunol       Date:  2012-03-28       Impact factor: 10.793

4.  2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome.

Authors:  Elias Jabbour; Srdan Verstovsek; Francis Giles; Varsha Gandhi; Jorge Cortes; Susan O'Brien; William Plunkett; Guillermo Garcia-Manero; C Ellen Jackson; Hagop Kantarjian; Michael Andreeff
Journal:  Cancer       Date:  2005-08-01       Impact factor: 6.860

5.  Hypereosinophilic syndrome: long-term remission following allogeneic stem cell transplant in spite of transient eosinophilia post-transplant.

Authors:  Maureen A Cooper; Luke P Akard; James M Thompson; Michael J Dugan; Jan Jansen
Journal:  Am J Hematol       Date:  2005-01       Impact factor: 10.047

6.  Treatment of patients with the hypereosinophilic syndrome with mepolizumab.

Authors:  Marc E Rothenberg; Amy D Klion; Florence E Roufosse; Jean Emmanuel Kahn; Peter F Weller; Hans-Uwe Simon; Lawrence B Schwartz; Lanny J Rosenwasser; Johannes Ring; Elaine F Griffin; Ann E Haig; Paul I H Frewer; Jacqueline M Parkin; Gerald J Gleich
Journal:  N Engl J Med       Date:  2008-03-16       Impact factor: 91.245

7.  Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome.

Authors:  Amy D Klion; Jamie Robyn; Cem Akin; Pierre Noel; Margaret Brown; Melissa Law; Dean D Metcalfe; Cynthia Dunbar; Thomas B Nutman
Journal:  Blood       Date:  2003-09-22       Impact factor: 22.113

8.  Long-term follow-up of patients with hypereosinophilic syndrome treated with Alemtuzumab, an anti-CD52 antibody.

Authors:  Paolo Strati; Jorge Cortes; Stefan Faderl; Hagop Kantarjian; Srdan Verstovsek
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2012-11-01

9.  Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy.

Authors:  Princess U Ogbogu; Bruce S Bochner; Joseph H Butterfield; Gerald J Gleich; Johannes Huss-Marp; Jean Emmanuel Kahn; Kristin M Leiferman; Thomas B Nutman; Florian Pfab; Johannes Ring; Marc E Rothenberg; Florence Roufosse; Marie-Helene Sajous; Javed Sheikh; Dagmar Simon; Hans-Uwe Simon; Miguel L Stein; Andrew Wardlaw; Peter F Weller; Amy D Klion
Journal:  J Allergy Clin Immunol       Date:  2009-12       Impact factor: 10.793

10.  Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders.

Authors:  Animesh Pardanani; Terra Reeder; Luis F Porrata; Chin-Yang Li; Henry D Tazelaar; E Joanna Baxter; Thomas E Witzig; Nicholas C P Cross; Ayalew Tefferi
Journal:  Blood       Date:  2002-12-27       Impact factor: 22.113

  10 in total
  2 in total

1.  Case for diagnosis. Erythroderma as manifestation of hypereosinophilic syndrome.

Authors:  Maira Renata Merlotto; Lucas Oliveira Cantadori; Delmo Sakabe; Hélio Amante Miot
Journal:  An Bras Dermatol       Date:  2018-06       Impact factor: 1.896

2.  Diffuse Exfoliative Rash with Sepsis and Eosinophilia: A Case of Erythroderma?

Authors:  Jake Cho; Selsabeel A Elyaman; Stephen A Avera; Kenneth Iyamu
Journal:  Am J Case Rep       Date:  2019-09-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.